The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More

Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More

February 8, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

New data from a post-marketing safety study evaluating the long-term effects of tofacitinib on heart disease, malignancies and serious infections found the treatment did not prove non-inferior to tumor necrosis factor (TNF) inhibitors. The randomized, open-label study was conducted in adults with rheumatoid arthritis (RA) taking either 5 or 10 mg doses of tofacitinib twice daily.1

You Might Also Like
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
  • Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events
  • Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments
Explore This Issue
March 2021
Also By This Author
  • Mirikizumab Promising for Plaque Psoriasis

Background: In November 2012, tofacitinib was initially approved by U.S. Food & Drug Administration (FDA) to treat moderate to severe active RA in adults who are intolerant to methotrexate and for whom methotrexate proved inadequate. The treatment, a 5 mg dose taken twice daily, was approved for use as monotherapy and combination therapy with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). The FDA asked Pfizer, the manufacturer of tofacitinib, to conduct a post-marketing study examining the agent’s cardiovascular risks.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Additional FDA approvals for tofacitinib include for the treatment of psoriatic arthritis, ulcerative colitis and polyarticular course juvenile idiopathic arthritis.3 In 2019, the FDA added new safety information to its label. This new boxed warning outlined the risk of thrombosis, pulmonary embolism and all-cause mortality associated with tofacitinib use for RA patients taking 10 mg of tofacitinib twice daily compared with those taking 5 mg of tofacitinib twice daily or TNF inhibitors.4

The Study
The phase 3B/4 ORAL Surveillance (A3921133; NCT02092467) study assessed the risk of cardiovascular events and malignancies when taking tofacitinib.5 Researchers randomized 4,362 RA patients. Each patient was older than 50, taking background methotrexate and had at least one additional cardiovascular risk factor. Adverse events were pooled for the two tofacitinib doses (5 or 10 mg taken twice daily) when evaluating the primary endpoints, which were non-inferiority compared with TNF inhibitors (etanercept or adalimumab).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Incidence rates for major adverse cardiovascular events were slightly higher with the 10 mg of tofacitinib vs. 5 mg of tofacitinib (10.5 vs. 9.1 per 1,000 person-years), while the rates of malignancies were not different between the two tofacitinib doses. The primary analysis included 135 patients with major adverse cardiovascular events and 164 patients with malignancies, excluding non-melanoma skin cancer. For tofacitinib, myocardial infarction was the most frequently reported major adverse cardiovascular event, and lung cancer was the most frequently reported malignancy.

Additionally, the results showed tofacitinib-treated patients had significantly higher rates of adjudicated malignancies than patients who took an TNF inhibitor (11.3 vs. 7.7 per 1,000 person-years of drug exposure; hazard ratio [HR] 1.48, 95% confidence interval [CI] 1.04–2.09), as well as numerically higher rates of major adverse cardiovascular events. The rates of major adverse cardiovascular events were 9.8 vs. 7.3 per 1,000 person-years (HR 1.33, 95% CI 0.91–1.94) for tofacitinib and TNF inhibitors, respectively. For tofacitinib, major adverse cardiovascular events did not meet the trial’s criteria for non-inferiority.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Cardiovascular disease, Heart Disease, risk, TofacitinibIssue: March 2021

You Might Also Like:
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
  • Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events
  • Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments
  • Tofacitinib Shows Ongoing Action Against Plaque Psoriasis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.